A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy

Westhoff, Mike-Andrew; Karpel-Massler, Georg; Brühl, Oliver; Enzenmüller, Stefanie; La Ferla-Brühl, Katia; Siegelin, Markus D.; Nonnenmacher, Lisa; Debatin, Klaus-Michael

Members of the PI3K/Akt/mTor signaling cascade are among the most frequently altered proteins in cancer, yet the therapeutic application of pharmacological inhibitors of this signaling network, either as monotherapy or in combination therapy (CT) has so far not been particularly successful. In this review we will focus on the role of PI3K/Akt/mTOR in two distinct tumors, Glioblastoma multiforme (GBM), an adult brain tumor which frequently exhibits PTEN inactivation, and Neuroblastoma (NB), a childhood malignancy that affects the central nervous system and does not harbor any classic alterations in PI3K/Akt signaling. We will argue that inhibitors of PI3K/Akt signaling can be components for potentially promising new CTs in both tumor entities, but further understanding of the signal cascade’s complexity is essential for successful implementation of these CTs. Importantly, failure to do this might lead to severe adverse effects, such as treatment failure and enhanced therapy resistance.


  • thumnail for binary/octet-stream 1.98 MB Download File

Also Published In

Molecular and Cellular Therapies

More About This Work

Academic Units
Pathology and Cell Biology
BioMed Central
Published Here
November 4, 2014


PI3K, Glioblastoma, Neuroblastoma, Cancer, Pharmacological inhibitors, Signaling cascade